References
- Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
- Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. [Database]. Lancet. 2008;17371:1695–1709.
- Moreira J, Tobias A, O'Brien MP, et al. Targeted therapy in head and neck cancer: an update on current clinical developments in epidermal growth factor receptor-targeted therapy and immunotherapies. Drugs. 2017;77:843–857.
- Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015;33:3293–3304.
- Mandapathil M, Szczepanski MJ, Szajnik M, et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res. 2009;15:6348–6357.
- Strauss L, Bergmann C, Gooding W, et al. The frequency and suppressor function of CD4 + CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6301–6311.
- Wang Y, Sun J, Zheng R, et al. Regulatory T cells are an important prognostic factor in breast cancer: a systematic review and meta-analysis. NEO. 2016;63:789–798.
- Fortuna L, Relf J, Chang YM, et al. Prevalence of FoxP3(+) cells in canine tumours and lymph nodes correlates positively with glucose transporter 1 expression. J Comp Pathol. 2016;155:171–180.
- Hanagiri T, Fukumoto M, Koyanagi Y, et al. Regulatory T-cells and micrometastasis in lymph nodes of stage I NSCLC. Anticancer Res. 2014;34:7185–7190.
- Sakaguchi S. The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J Clin Invest. 2003;112:1310–1312.
- Weller P, Bankfalvi A, Gu X, et al. The role of tumour FoxP3 as prognostic marker in different subtypes of head and neck cancer. Eur J Cancer. 2014;50:1291–1300.
- Chen J, Chen Z. The effect of immune microenvironment on the progression and prognosis of colorectal cancer. Med Oncol. 2014;31:82.
- Schipmann S, Wermker K, Schulze HJ, et al. Cutaneous and oral squamous cell carcinoma-dual immunosuppression via recruitment of FOXP3+ regulatory T cells and endogenous tumour FOXP3 expression? J Craniomaxillofac Surg. 2014;42:1827–1833.
- Wang WL, Chang WL, Yang HB, et al. Quantification of tumor infiltrating Foxp3+ regulatory T cells enables the identification of high-risk patients for developing synchronous cancers over upper aerodigestive tract. Oral Oncol. 2015;51:698–703.
- Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol. 2012;22:327–334.
- Pesenacker AM, Cook L, Levings MK. The role of FOXP3 in autoimmunity. Curr Opin Immunol. 2016;43:16–23.
- Manjili MH, Butler SE. Role of Tregs in cancer dormancy or recurrence. Immunol Invest. 2016;45:759–766.
- Wolf GT, Chepeha DB, Bellile E, et al. Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study. Oral Oncol. 2015;51:90–95.
- Lee HE, Park DJ, Kim WH, et al. High FOXP3+ regulatory T-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer. Br J Cancer. 2011;105:413–419.
- Heeren AM, de Boer E, Bleeker MC, et al. Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area. Oncotarget. 2015;6:32484–32493.